<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical strategy to build an individualized treatment regimen for MDR-TB</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical strategy to build an individualized treatment regimen for MDR-TB</h1>
<div class="graphic"><div class="figure"><div class="ttl">Clinical strategy to build an individualized treatment regimen for MDR-TB</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="50%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="2"> <ul> <li>If a standardized short course regimen (such as BPaL: bedaquiline, pretonamid, and linezolid) cannot be used due to drug resistance, drug intolerance or limited drug availability, an individualized regimen may be created according to the following <span class="nowrap_whitespace">principles<sup>[1,2]</sup>.</span> <ul> <li>Build a regimen using <strong>five or more drugs</strong> to which the isolate is susceptible (or has low likelihood of resistance), preferably with drugs that have not been used to treat the patient previously.</li> <li>The choice of drugs is contingent on capacity to monitor for adverse effects, patient comorbidities, and values/preferences (therefore, choices are subject to program and safety limitations).</li> <li>Among children with TB disease who are contacts of MDR-TB source cases, if an isolate cannot be obtained from the child, the source case's isolate DST result should be used.</li> <li>TB expert medical consultation is recommended.</li> </ul> </li> </ul> </td> </tr> <tr> <td class="divider_bottom" rowspan="2"><strong>Step 1:</strong> Choose one later-generation fluoroquinolone</td> <td>Levofloxacin</td> </tr> <tr class="divider_bottom"> <td>Moxifloxacin</td> </tr> <tr> <td class="divider_bottom" rowspan="2"><strong>Step 2:</strong> Choose both of these prioritized drugs</td> <td>Bedaquiline</td> </tr> <tr class="divider_bottom"> <td>Linezolid</td> </tr> <tr> <td class="divider_bottom" rowspan="2"><strong>Step 3:</strong> Choose both of these prioritized drugs</td> <td>Clofazimine</td> </tr> <tr class="divider_bottom"> <td>Cycloserine/terizidone</td> </tr> <tr> <td class="divider_bottom" rowspan="7"><strong>Step 4:</strong> If needed, use the following <span class="nowrap_whitespace">drugs<sup>¶</sup></span></td> <td>Pyrazinamide</td> </tr> <tr> <td>Delamanid<sup>Δ</sup></td> </tr> <tr> <td>Ethambutol</td> </tr> <tr> <td>Ethionamide or <span class="nowrap_whitespace">prothionamide<sup>◊</sup></span></td> </tr> <tr> <td> <p>Imipenem-cilastatin or <span class="nowrap_whitespace">meropenem<sup>§</sup></span></p> <p>plus</p> Clavulanic acid (available only when combined with amoxicillin, as amoxicillin-clavulanic acid)</td> </tr> <tr> <td>p-Aminosalicylic acid<sup>¥</sup></td> </tr> <tr class="divider_bottom"> <td>High-dose isoniazid<sup>‡</sup></td> </tr> <tr> <td class="divider_bottom" rowspan="2"><strong>Step 5:</strong> If a regimen cannot be assembled with five effective oral drugs, <strong>and the isolate is susceptible</strong>, use one of these injectable agents*</td> <td>Amikacin</td> </tr> <tr class="divider_bottom"> <td>Streptomycin</td> </tr> <tr> <td rowspan="3">These drugs are no longer recommended for inclusion in MDR-TB regimens:</td> <td>Capreomycin and kanamycin</td> </tr> <tr> <td>Amoxicillin-clavulanate (when used without a carbapenem)</td> </tr> <tr> <td>Azithromycin and clarithromycin</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>TB: tuberculosis; MDR: multidrug-resistant; DST: drug susceptibility testing; PS: propensity score; IPDMA: individual patient data meta-analyses; INH: isoniazid.</p>
<p>* Amikacin and streptomycin should be used only when the patient's isolate is susceptible to these drugs. Because of their toxicity, these drugs should be reserved for when more-effective or less-toxic therapies cannot be assembled to achieve a total of five effective drugs.</p>
<p>¶ Patient preferences in terms of the harms and benefits associated with injectables (the use of which is no longer obligatory), the capacity to appropriately monitor for significant adverse effects, consideration of drug–drug interactions, and patient comorbidities should be considered in selecting Step 4 agents over injectables. Ethambutol and pyrazinamide had mixed/marginal performance on outcomes assessed in our PS-matched IPDMA; however, some experts may prefer these drugs over injectable agents to build a regimen of at least five effective oral drugs. Use pyrazinamide and ethambutol only when the isolate is documented as susceptible.</p>
<p>Δ Data on dosing and safety of delamanid are available in children &gt;3 years of age.</p>
<p>◊ Mutations in the inhA region of the Mycobacterium tuberculosis genome can confer resistance to ethionamide/prothionamide as well as to INH. In this situation, ethionamide/prothionamide may not be a good choice unless the isolate is shown to be susceptible with in vitro testing.</p>
<p>§ Divided daily intravenous dosing limits feasibility. Optimal duration of use not defined.</p>
<p>¥ Fair/poor tolerability and low performance. Adverse effects reported to be less common in children.</p>
‡ Data not reviewed in our PS-matched IPDMA, but high-dose isoniazid can be considered despite low-level isoniazid resistance but not with high-level INH resistance.</div><div class="graphic_reference"><p>Adapted with permission of the American Thoracic Society. Copyright © 2019 American Thoracic Society. From: Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis: an official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med 2019; 200:e93. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.</p>
References:
<ol>
<li>Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis: an official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med 2019; 200:e93. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.</li>
<li>Mirzayev F, Viney K, Linh NN, et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J 2021; 57:2003300.</li>
</ol></div><div id="graphicVersion">Graphic 119120 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
